Mnemosyne Pharmaceuticals is developing novel therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders. We target subtypes of the NMDA receptor, essential mediators of brain plasticity. Our company’s lead program is focused on depression, while schizophrenia and autism spectrum disorders such as Rett syndrome are also areas of discovery.